Dr. Hirsch joined Alpha-9 from Longitude Capital where he currently serves as a Venture Partner. During his time at Longitude, he served on the board of more than 10 biotechnology companies. Prior to Longitude Capital, he was a Vice President at Pequot Ventures and an Engagement Manager in the pharmaceutical practice of McKinsey. Dr. Hirsch holds a PhD in Biology from the Massachusetts Institute of Technology, an MD from Harvard Medical School, and a BA in Biology from Johns Hopkins University.

• 

  Chief Executive Officer (CEO) in Alpha-9 Oncology

  Harnessing the Power of Radiopharmaceuticals